{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:30:24Z","timestamp":1783398624910,"version":"3.54.6"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The objective of the current study was to detect plasma profiles of inflammatory cytokines for determining potential biomarkers indicating cancer presence among the anti-TIF1-\u03b3 antibody-positive dermatomyositis (DM) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty-seven cancer-associated anti-TIF1-\u03b3 antibody-positive DM (Cancer TIF1-\u03b3-DM) patients were compared with 20 anti-TIF1-\u03b3 antibody-positive DM patients without cancer (Non-cancer TIF1-\u03b3-DM) and 10 healthy controls (HC). The plasma levels of 17 cytokines were determined using the Luminex 200 system. The ability of plasma VEGF-A, TNF-\u03b1, CCL2, IL-6, and IFN-\u03b3 levels to distinguish the presence of cancer was evaluated through the area under the curve (AUC) analysis. Potential protein interactions of TIF1-\u03b3 and the five cytokines were analyzed using the STRING database.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>VEGF-A, TNF-\u03b1, CCL2, IL-6, and IFN-\u03b3 plasma levels were significantly higher in the Cancer TIF1-\u03b3-DM group, especially those without any anticancer treatment, than those in the non-cancer TIF1-\u03b3-DM and HC groups. Meanwhile, anti-TIF1-\u03b3 antibody and the five cytokines could distinguish cancer presence in anti-TIF1-\u03b3 antibody-positive DM patients. The STRING network indicated that TIF1-\u03b3 potentially interacted with the cytokines. Positive correlations of VEGF-A among CCL2, IL-6, and IFN-\u03b3 and between IFN-\u03b3 and IL-6 were observed in Cancer TIF1-\u03b3-DM patients. VEGF-A, TNF-\u03b1, CCL2, and IL-6 were positively associated with muscle-associated enzymes among the Cancer TIF1-\u03b3-DM patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The present study identified VEGF-A, TNF-\u03b1, CCL2, IL-6, and IFN-\u03b3 as significant potential biomarkers indicating the presence of cancer and demonstrated a more detailed cytokine profile during diagnosis. These biomarkers could provide better screening strategies and insight into the Cancer TIF1-\u03b3-DM pathogenesis.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td align=\"left\" colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 VEGF-A, TNF-\u03b1, CCL2, IL-6, and IFN-\u03b3 are potential biomarkers of cancer in cancer-associated anti-TIF1-\u03b3 antibody-positive dermatomyositis.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s10067-022-06425-3","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T01:02:42Z","timestamp":1668128562000},"page":"817-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Circulating VEGF-A, TNF-\u03b1, CCL2, IL-6, and IFN-\u03b3 as biomarkers of cancer in cancer-associated anti-TIF1-\u03b3 antibody-positive dermatomyositis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3966-2864","authenticated-orcid":false,"given":"Xiaomeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songxin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liubing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoting","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8267-0985","authenticated-orcid":false,"given":"Yongzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"6425_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","volume":"82","author":"ME DeWane","year":"2020","unstructured":"DeWane ME, Waldman R, Lu J (2020) Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 82:267\u2013281 (In eng)","journal-title":"J Am Acad Dermatol"},{"key":"6425_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J et al (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Prim 7:86 (In eng)","journal-title":"Nat Rev Dis Prim"},{"key":"6425_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1203475416665601","volume":"21","author":"JK Qiang","year":"2017","unstructured":"Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg 21:131\u2013136 (In eng)","journal-title":"J Cutan Med Surg"},{"key":"6425_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","volume":"357","author":"CL Hill","year":"2001","unstructured":"Hill CL, Zhang Y, Sigurgeirsson B et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet (London, England) 357:96\u2013100 (In eng)","journal-title":"Lancet (London, England)"},{"key":"6425_CR5","doi-asserted-by":"crossref","unstructured":"Opinc AH, Makowska JS (2022) Update on malignancy in myositis-well-established association with unmet needs. Biomolecules 12 (In eng)","DOI":"10.3390\/biom12010111"},{"key":"6425_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/art.33379","volume":"64","author":"E Trallero-Aragu\u00e1s","year":"2012","unstructured":"Trallero-Aragu\u00e1s E, Rodrigo-Pend\u00e1s J, Selva-O'Callaghan A et al (2012) Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 64:523\u2013532 (In eng)","journal-title":"Arthritis Rheum"},{"key":"6425_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/1744666X.2019.1699059","volume":"16","author":"T Gono","year":"2020","unstructured":"Gono T, Kuwana M (2020) Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis. Expert Rev Clin Immunol 16:79\u201389 (In eng)","journal-title":"Expert Rev Clin Immunol"},{"key":"6425_CR8","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s10067-019-04503-7","volume":"38","author":"S Li","year":"2019","unstructured":"Li S, Ge Y, Yang H et al (2019) The spectrum and clinical significance of myositis-specific autoantibodies in chinese patients with idiopathic inflammatory myopathies. Clin Rheumatol 38:2171\u20132179 (In eng)","journal-title":"Clin Rheumatol"},{"key":"6425_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/BOR.0000000000000744","volume":"32","author":"LA Cerezo","year":"2020","unstructured":"Cerezo LA, Vencovsk\u00fd J, \u0160enolt L (2020) Cytokines and inflammatory mediators as promising markers of polymyositis\/dermatomyositis. Curr Opin Rheumatol 32:534\u2013541 (In eng)","journal-title":"Curr Opin Rheumatol"},{"key":"6425_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet (London, England) 362:971\u2013982 (In eng)","journal-title":"Lancet (London, England)"},{"key":"6425_CR11","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1093\/rheumatology\/keab625","volume":"61","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Chen Y, Diao L et al (2022) Identification of distinct cytokine\/chemokine profiles in dermatomyositis with anti-transcriptional intermediary factor 1-\u03b3 antibody. Rheumatology (Oxford, England) 61:2176\u20132184 (In eng)","journal-title":"Rheumatology (Oxford, England)"},{"key":"6425_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.semcancer.2019.05.006","volume":"64","author":"S Tabrez","year":"2020","unstructured":"Tabrez S, Jabir NR, Khan MI et al (2020) Association of autoimmunity and cancer: an emphasis on proteolytic enzymes. Semin Cancer Biol 64:19\u201328 (In eng)","journal-title":"Semin Cancer Biol"},{"key":"6425_CR13","doi-asserted-by":"publisher","first-page":"4375120","DOI":"10.1155\/2016\/4375120","volume":"2016","author":"MA Rahat","year":"2016","unstructured":"Rahat MA, Shakya J (2016) Parallel aspects of the microenvironment in cancer and autoimmune disease. Mediat Inflamm 2016:4375120 (In eng)","journal-title":"Mediat Inflamm"},{"key":"6425_CR14","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1093\/rheumatology\/keab260","volume":"60","author":"N Cordel","year":"2021","unstructured":"Cordel N, Derambure C, Coutant S et al (2021) Trim33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-tif1\u03b3 positive cancer-associated dermatomyositis. Rheumatology (Oxford, England) 60:5863\u20135867 (In eng)","journal-title":"Rheumatology (Oxford, England)"},{"key":"6425_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","volume":"57","author":"I Pinal-Fernandez","year":"2018","unstructured":"Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E et al (2018) Tumour tif1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford, England) 57:388\u2013396 (In eng)","journal-title":"Rheumatology (Oxford, England)"},{"key":"6425_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jdermsci.2021.10.003","volume":"104","author":"NTM Ly","year":"2021","unstructured":"Ly NTM, Ma N, Ueda-Hayakawa I et al (2021) Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-tif1\u03b3 antibodies. J Dermatol Sci 104:177\u2013184 (In eng)","journal-title":"J Dermatol Sci"},{"key":"6425_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347 (In eng)","journal-title":"N Engl J Med"},{"key":"6425_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403\u2013407 (In eng)","journal-title":"N Engl J Med"},{"key":"6425_CR19","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M et al (2017) 2017 European league against rheumatism\/american college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955\u20131964 (In eng)","journal-title":"Ann Rheum Dis"},{"key":"6425_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/ard.2006.068502","volume":"66","author":"H Chinoy","year":"2007","unstructured":"Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66:1345\u20131349 (In eng)","journal-title":"Ann Rheum Dis"},{"key":"6425_CR21","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/BOR.0000000000000535","volume":"30","author":"A Selva-O'Callaghan","year":"2018","unstructured":"Selva-O'Callaghan A, Martinez-G\u00f3mez X, Trallero-Aragu\u00e1s E, Pinal-Fern\u00e1ndez I (2018) The diagnostic work-up of cancer-associated myositis. Curr Opin Rheumatol 30:630\u2013636 (In eng)","journal-title":"Curr Opin Rheumatol"},{"key":"6425_CR22","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/1346-8138.15284","volume":"47","author":"N Ikeda","year":"2020","unstructured":"Ikeda N, Yamaguchi Y, Kanaoka M et al (2020) Clinical significance of serum levels of anti-transcriptional intermediary factor 1-\u03b3 antibody in patients with dermatomyositis. J Dermatol 47:490\u2013496 (In eng)","journal-title":"J Dermatol"},{"key":"6425_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/rheumatology\/ket383","volume":"53","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Oddis CV, Goudeau D et al (2014) Anti-transcription intermediary factor 1-gamma autoantibody elisa development and validation. Rheumatology (Oxford, England) 53:433\u2013437 (In eng)","journal-title":"Rheumatology (Oxford, England)"},{"key":"6425_CR24","doi-asserted-by":"crossref","unstructured":"Huntington KE, Louie AD, Lee CG, Elias JA, Ross EA, El-Deiry WS (2021) Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with sars-cov-2. eLife 10 (In eng)","DOI":"10.7554\/eLife.64958"},{"key":"6425_CR25","first-page":"165","volume":"12","author":"P Amerio","year":"2002","unstructured":"Amerio P, Girardelli CR, Proietto G et al (2002) Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis. Eur J Dermatol: EJD 12:165\u2013169 (In eng)","journal-title":"Eur J Dermatol: EJD"},{"key":"6425_CR26","volume-title":"Statpearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2022","author":"K Tishkowski","year":"2022","unstructured":"Tishkowski K, Gupta V (2022) Erythrocyte sedimentation rate. In: Statpearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2022. StatPearls Publishing LLC"},{"key":"6425_CR27","first-page":"67","volume":"38","author":"L Dani","year":"2020","unstructured":"Dani L, Holmqvist M, Mart\u00ednez MA et al (2020) Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study. Clin Exp Rheumatol 38:67\u201373 (In eng)","journal-title":"Clin Exp Rheumatol"},{"key":"6425_CR28","doi-asserted-by":"publisher","first-page":"100695","DOI":"10.1016\/j.adro.2021.100695","volume":"6","author":"N Tomita","year":"2021","unstructured":"Tomita N, Tamechika SY, Kawakita D, Saito K (2021) Marked improvement of anti-tif1-\u03b3 antibody-positive dermatomyositis after chemoradiotherapy to relevant nasopharyngeal cancer. Adv Radiat Oncol 6:100695 (In eng)","journal-title":"Adv Radiat Oncol"},{"key":"6425_CR29","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/BOR.0000000000000641","volume":"31","author":"X Lu","year":"2019","unstructured":"Lu X, Peng Q, Wang G (2019) The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome. Curr Opin Rheumatol 31:643\u2013649 (In eng)","journal-title":"Curr Opin Rheumatol"},{"key":"6425_CR30","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/sj.bjc.6603923","volume":"97","author":"C Kut","year":"2007","unstructured":"Kut C, Mac Gabhann F, Popel AS (2007) Where is vegf in the body? A meta-analysis of vegf distribution in cancer. Br J Cancer 97:978\u2013985 (In eng)","journal-title":"Br J Cancer"},{"key":"6425_CR31","doi-asserted-by":"publisher","first-page":"e11775","DOI":"10.1097\/MD.0000000000011775","volume":"97","author":"KX Chai","year":"2018","unstructured":"Chai KX, Chen YQ, Fan PL, Yang J, Yuan X (2018) Strobe: the correlation of cyr61, ctgf, and vegf with polymyositis\/dermatomyositis. Medicine 97:e11775 (In eng)","journal-title":"Medicine"},{"key":"6425_CR32","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1002\/art.23884","volume":"58","author":"C Grundtman","year":"2008","unstructured":"Grundtman C, Tham E, Ulfgren AK, Lundberg IE (2008) Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum 58:3224\u20133238 (In eng)","journal-title":"Arthritis Rheum"},{"key":"6425_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9:361\u2013371 (In eng)","journal-title":"Nat Rev Cancer"},{"key":"6425_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s004010051165","volume":"99","author":"S Kuru","year":"2000","unstructured":"Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99:585\u2013588 (In eng)","journal-title":"Acta Neuropathol"},{"key":"6425_CR35","doi-asserted-by":"publisher","unstructured":"Zhao Q, Chen Y, Diao L et al (2021) Identification of distinct cytokine\/chemokine profiles in dermatomyositis with anti-transcriptional intermediary factor 1-\u03b3 antibody. Rheumatology 61(5):2176\u20132184.\u00a0https:\/\/doi.org\/10.1093\/rheumatology\/keab625. (In eng)","DOI":"10.1093\/rheumatology\/keab625"},{"key":"6425_CR36","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1212\/WNL.58.12.1779","volume":"58","author":"JL De Bleecker","year":"2002","unstructured":"De Bleecker JL, De Paepe B, Vanwalleghem IE, Schr\u00f6der JM (2002) Differential expression of chemokines in inflammatory myopathies. Neurology 58:1779\u20131785 (In eng)","journal-title":"Neurology"},{"key":"6425_CR37","doi-asserted-by":"publisher","first-page":"2124390","DOI":"10.1155\/2018\/2124390","volume":"2018","author":"E Lubowicka","year":"2018","unstructured":"Lubowicka E, Przylipiak A, Zajkowska M et al (2018) Plasma chemokine ccl2 and its receptor ccr2 concentrations as diagnostic biomarkers for breast cancer patients. Biomed Res Int 2018:2124390 (In eng)","journal-title":"Biomed Res Int"},{"key":"6425_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/cmi.2017.135","volume":"15","author":"T Yoshimura","year":"2018","unstructured":"Yoshimura T (2018) The chemokine mcp-1 (ccl2) in the host interaction with cancer: a foe or ally? Cell Mol Immunol 15:335\u2013345 (In eng)","journal-title":"Cell Mol Immunol"},{"key":"6425_CR39","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s10067-020-05339-2","volume":"40","author":"J Bai","year":"2021","unstructured":"Bai J, Wu C, Zhong D, Xu D, Wang Q, Zeng X (2021) Hierarchical cluster analysis of cytokine profiles reveals a cutaneous vasculitis-associated subgroup in dermatomyositis. Clin Rheumatol 40:999\u20131008 (In eng)","journal-title":"Clin Rheumatol"},{"key":"6425_CR40","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ (2018) Recent insights into targeting the il-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 18:773\u2013789 (In eng)","journal-title":"Nat Rev Immunol"},{"key":"6425_CR41","doi-asserted-by":"publisher","first-page":"101280","DOI":"10.1016\/j.smim.2019.05.002","volume":"43","author":"JD Burke","year":"2019","unstructured":"Burke JD, Young HA (2019) Ifn-\u03b3: a cytokine at the right time, is in the right place. Semin Immunol 43:101280 (In eng)","journal-title":"Semin Immunol"},{"key":"6425_CR42","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.cell.2016.01.049","volume":"164","author":"AK Palucka","year":"2016","unstructured":"Palucka AK, Coussens LM (2016) The basis of oncoimmunology. Cell 164:1233\u20131247 (In eng)","journal-title":"Cell"},{"key":"6425_CR43","doi-asserted-by":"crossref","unstructured":"Galdiero MR, Marone G, Mantovani A (2018) Cancer inflammation and cytokines. Cold Spring Harb Perspect Biol 10 (In eng)","DOI":"10.1101\/cshperspect.a028662"},{"key":"6425_CR44","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1128\/MCB.17.7.4015","volume":"17","author":"S Yoshida","year":"1997","unstructured":"Yoshida S, Ono M, Shono T et al (1997) Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17:4015\u20134023 (In eng)","journal-title":"Mol Cell Biol"},{"key":"6425_CR45","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","volume":"60","author":"AGS Oldroyd","year":"2021","unstructured":"Oldroyd AGS, Allard AB, Callen JP et al (2021) A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford, England) 60:2615\u20132628 (In eng)","journal-title":"Rheumatology (Oxford, England)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06425-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T09:07:52Z","timestamp":1676538472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06425-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["6425"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06425-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"7 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This study was approved by the Research Ethics Commission of PUMCH (JS-2156).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}